The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

Bayer begins phase I study targeting GPC3 with actinium-225 radiopharmaceutical in patients with advanced hepatocellular carcinoma: Berlin Wednesday, April 30, 2025, 12:00 Hrs [IS ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an ...

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 ...

The USFDA conducted a surveillance inspection at the group's API Unit, located at Dabhasa in Gujarat. The inspection was ...

ITM Isotope Technologies Munich, Alpha-9 Oncology sign supply agreement for therapeutic medical radioisotope Actinium-225: Munich, Germany Saturday, April 26, 2025, 10:00 Hrs [IST ...

Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a ...